Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo

Thrombosis Research

Volumn 127, Issue 6, 2011, Pages 565-570

  Kim, Chae Wook ^a   Yun, Jun Won ^a   Bae, Il Hong ^a   Park, Yang Hui ^a   Jeong, Yeon Su ^a   Park, Jin Woo ^a   Chung, Jin Ho ^b   Park, Young Ho ^a   Lim, Kyung Min ^a  

^a AmorePacific Corporation   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; COLLAGEN; FERRIC CHLORIDE;

ANALYTICAL EQUIPMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING TIME; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; DRUG SCREENING; EX VIVO STUDY; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; SPECIES DIFFERENCE; THROMBOCYTE AGGREGATION; VEIN THROMBOSIS; WHOLE BLOOD AGGREGOMETER;

ANIMALS; BLOOD PLATELETS; CHLORIDES; FERRIC COMPOUNDS; FIBRINOLYTIC AGENTS; MALE; MICE; MICE, INBRED C57BL; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES; THROMBOSIS;

EID: 79957613194     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.02.004     Document Type: Article

References (24)

1. Bramer SL, Tata PN, Vengurlekar SS, Brisson JH. Method for the quantitative analysis of cilostazol and its metabolites in human plasma using LC/MS/MS. J Pharm Biomed Anal. 2001;26:(4)637-650. (Pubitemid 32763234)
2. Cariski AT. Cilostazol: a novel treatment option in intermittent claudication. Int J Clin Pract. 2001;119:11-18 Suppl.
3. EvaluatePharma. Anti-Thrombotic Agent Market; 2009.
4. Hennan JK, Morgan GA, Swillo RE, Antrilli TM, Mugford C, Vlasuk GP, et al. Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost. 2008;6:(9)1558-1564.
5. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des. 2003;9:(28)2289-2302. (Pubitemid 37236353)
6. Lee JH, Park SY, Shin HK, Kim CD, Lee WS, Hong KW. Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury. CNS Neurosci Ther. 2008;14:(2)143-152. (Pubitemid 351713318)
7. Lindenblatt N, Schareck W, Belusa L, Nickels RM, Menger MD, Vollmar B. Antioxidant ebselen delays microvascular thrombus formation in the rat cremaster muscle by inhibiting platelet P-selectin expression. Thromb Haemost. 2003;90:(5) 882-892. (Pubitemid 37427858)
8. Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev. 2001;19:(4)369-386. (Pubitemid 34260705)
9. Matsumoto Y, Marukawa K, Okumura H, Adachi T, Tani T, Kimura Y. Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses. Thromb Res. 1999;95:(1)19-29. (Pubitemid 29325257)
10. Mehta J, Li D, Mehta JL. Vitamins C and E prolong time to arterial thrombosis in rats. J Nutr. 1999;129:(1)109-112. (Pubitemid 29044766)
11. Minami N, Suzuki Y, Yamamoto M, Kihira H, Imai E, Wada H, et al. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci. 1997;61:(25)PL 383-389. (Pubitemid 28122473)
12. Nishi T, Kimura Y, Nakagawa K. Research and development of cilostazol: an antiplatelet agent. Yakugaku Zasshi. 2000;120:(12)1247-1260.
13. Ofosu FA. The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences. Biochemistry (Mosc). 2002;67:(1)47-55.
14. Panzer-Knodle S, Taite BB, Mehrotra DV, Nicholson NS, Feigen LP. Species variation in the effect of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation. J Pharmacol Toxicol Methods. 1993;30:(1)47-53. (Pubitemid 23290771)
15. Ryu KH, Han HY, Lee SY, Jeon SD, Im GJ, Lee BY, et al. Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time. Thromb Res. 2009;124:(3)328-334.
16. Savi P, Pflieger AM, Herbert JM. cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coagul Fibrinolysis. 1996;7:(2)249-252. (Pubitemid 26167952)
17. Shakur Y, Fong M, Hensley J, Cone J, Movsesian MA, Kambayashi J, et al. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc Drugs Ther. 2002;16:(5) 417-427. (Pubitemid 36255742)
18. Sudo T, Ito H, Kimura Y. Characterization of platelet aggregation in whole blood of laboratory animals by a screen filtration pressuremethod. Platelets. 2003;14:(4)239-246. (Pubitemid 36791844)
19. Ting HJ, Khasawneh FT. Platelet function and Isoprostane biology. Should isoprostanes be the newest member of the orphan-ligand family? J Biomed Sci. 2010;17:(1)24.
20. Varanasi VS, Veeraraghavan S, Potharaju S, Thappali RS, Raghavan R, Vakkalanka VS. Validated high performance liquid chromatographic method for simultaneous determination of rosiglitazone, cilostazol, and 3, 4-dehydro-cilostazol in rat plasma and its application to pharmacokinetics. Arzneimittelforschung. 2008;58: (6)288-296. (Pubitemid 351961814)
21. Varani K, Gessi S, Dalpiaz A, Borea PA. Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding. Br J Pharmacol. 1996;117:(8)1693-1701.
22. Wang X, Smith PL, Hsu MY, Ogletree ML, Schumacher WA. Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxy-peptidase inhibitor. J Thromb Haemost. 2006;4:(2)403-410.
23. Watanabe T, Zhang N, Liu M, Tanaka R, Mizuno Y, Urabe T. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke. 2006;37:(6)1539-1545. (Pubitemid 44305739)
24. Westrick RJ, Winn ME, Eitzman DT. Murine models of vascular thrombosis (Eitzman series). Arterioscler Thromb Vasc Biol. 2007;27:(10)2079-2093. (Pubitemid 350287234)